Letter

Adjuvant trastuzumab for breast cancer: An increasingly common ethical and economic conundrum

BMJ 2005; 331 doi: 10.1136/bmj.331.7526.1202-b (Published 17 November 2005)
Cite this as: BMJ 2005;331:1202.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Matthew L Grove (Matthew.Grove@northumbria-healthcare.nhs.uk), consultant rheumatologist
  1. Tyneside General Hospital, North Shields NE29 8NH

    EDITOR—The advent of increasingly expensive and effective treatments over the next few years is likely to make this kind of ethical discussion even more common.1

    However, the £20 000 headline figure for a course of trastuzumab obscures the real cost of using this agent. In the original paper 261 adverse outcomes occurred in 1679 patients …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular